Pharmaceuticals News and Research

RSS

MedTera, HealthPrize Technologies partner to help patients self-manage their diseases

MedTera, an integrated marketing solutions company dedicated to improving education, promotion and communications in the healthcare, life sciences and pharmaceutical industries, today announced its formal partnership with HealthPrize Technologies, a web-based software company that motivates people to fill and stay on prescription medications.

29 Jul 2010

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford.

29 Jul 2010

Mylan second-quarter adjusted diluted EPS increases to $0.37

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

29 Jul 2010

China PharmaHub to close Merger Agreement with World Wide Relics in August 2010

China PharmaHub Corp., a pharmaceutical HUB between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, announced today that it has entered into a Merger Agreement with World Wide Relics, Inc.. The merger is expected to close in August 2010.

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

29 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

Scientists identify new catalytic process to create pharmaceuticals with less chemical waste

Much like two children in the back seat of a car, it can be challenging to get two catalysts to cooperate for the greater good. Now Northwestern University chemists have gotten two catalysts to work together on the same task -- something easily done by nature but a difficult thing to do in the laboratory.The findings, published by the journal Nature Chemistry, will allow medicinal chemists to invent new reactions and produce valuable bioactive compounds faster with less impact on the environment.

29 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010

HemaQuest closes additional $4M to Series B financing

HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.

28 Jul 2010

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the second quarter ended June 30, 2010. Net sales for the quarter were $968 million, and adjusted diluted earnings per share were $0.86.

28 Jul 2010

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2010.

28 Jul 2010

FDA approves Tris Pharma's first-time generic of Methylphenidate Hydrochloride Oral Solution

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin® Oral Solution marketed by Shionogi Pharmaceuticals, Inc.

28 Jul 2010

Dyax second-quarter total revenues increase to $15.1 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2010.

28 Jul 2010

ViroPharma second-quarter net sales increase 33% to $109.0 million

ViroPharma Incorporated reported today its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Pharmaceuticals News and Research

MedTera, HealthPrize Technologies partner to help patients self-manage their diseases

Sanofi-aventis U.S joins Dispensary of Hope's Continued Access Program

Mylan second-quarter adjusted diluted EPS increases to $0.37

China PharmaHub to close Merger Agreement with World Wide Relics in August 2010

Loss of key nerve cells cause Parkinson's disease: Research

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Etubics enters Phase I trials for next generation vector vaccines

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

Scientists identify new catalytic process to create pharmaceuticals with less chemical waste

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

HemaQuest closes additional $4M to Series B financing

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

FDA approves Tris Pharma's first-time generic of Methylphenidate Hydrochloride Oral Solution

Dyax second-quarter total revenues increase to $15.1 million

ViroPharma second-quarter net sales increase 33% to $109.0 million

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence